0	8	Biphasic	biphasic	JJ
9	16	control	control	NN
17	19	of	of	IN
20	27	nuclear	nuclear	JJ
28	40	factor-kappa	factor-kappa	NN
41	42	B	B	NNP
43	53	activation	activation	NN
54	56	by	by	IN
57	60	the	the	DT
61	62	T	t	NN
63	67	cell	cell	NN
68	76	receptor	receptor	NN
77	84	complex	complex	NN
84	85	:	:	:
86	90	role	role	NN
91	93	of	of	IN
94	99	tumor	tumor	NN
100	108	necrosis	necrosis	NN
109	115	factor	factor	NN
116	121	alpha	alpha	NN
121	122	.	.	.

124	127	The	the	DT
128	138	regulation	regulation	NN
139	141	of	of	IN
142	149	nuclear	nuclear	JJ
150	156	factor	factor	NN
157	158	(	(	(
158	167	NF)-kappa	NF)-kappa	NNP
168	169	B	B	NNP
170	180	activation	activation	NN
181	183	by	by	IN
184	187	the	the	DT
188	189	T	t	NN
190	194	cell	cell	NN
195	203	receptor	receptor	NN
204	205	(	(	(
205	213	TcR)/CD3	tcr)/cd3	NN
214	221	complex	complex	NN
222	224	in	in	IN
225	232	primary	primary	JJ
233	238	human	human	JJ
239	240	T	t	NN
241	246	cells	cell	NNS
247	250	has	have	VBZ
251	255	been	be	VBN
256	263	studied	study	VBN
264	266	at	at	IN
267	274	various	various	JJ
275	280	times	time	NNS
281	286	after	after	IN
287	297	activation	activation	NN
297	298	.	.	.

299	303	Only	only	RB
304	307	p50	p50	NN
308	316	NF-kappa	NF-kappa	NNP
317	318	B	B	NNP
319	326	protein	protein	NN
327	332	bound	bind	VBD
333	336	the	the	DT
337	342	kappa	kappa	NN
343	344	B	B	NNP
345	352	element	element	NN
353	355	of	of	IN
356	369	interleukin-2	interleukin-2	NN
370	378	receptor	receptor	NN
379	380	(	(	(
380	385	IL-2R	IL-2R	NNP
385	386	)	)	)
387	392	alpha	alpha	NN
393	398	chain	chain	NN
399	407	promoter	promoter	NN
408	410	on	on	IN
411	418	resting	rest	VBG
419	420	T	t	NN
421	426	cells	cell	NNS
426	427	.	.	.

428	435	However	however	RB
435	436	,	,	,
437	448	immediately	immediately	RB
449	454	after	after	IN
455	462	TcR/CD3	tcr/cd3	NN
463	476	cross-linking	cross-linking	NN
477	478	(	(	(
478	483	after	after	IN
484	497	approximately	approximately	RB
498	499	1	1	CD
500	501	h	h	NN
501	502	;	;	:
503	512	immediate	immediate	JJ
512	513	)	)	)
514	521	binding	binding	NN
522	524	of	of	IN
525	532	p50.p65	p50.p65	NN
533	545	heterodimers	heterodimer	NNS
546	549	was	be	VBD
550	559	observed.	observed.	VBN
560	569	p50.c-rel	p50.c-rel	NN
570	582	heterodimers	heterodimer	NNS
583	587	were	be	VBD
588	592	also	also	RB
593	601	detected	detect	VBN
602	607	bound	bind	VBN
608	610	to	to	TO
611	615	this	this	DT
616	624	sequence	sequence	NN
625	627	at	at	IN
628	633	early	early	JJ
634	638	time	time	NN
639	645	points	point	NNS
646	647	(	(	(
647	651	7-16	7-16	CD
652	653	h	h	NN
653	654	;	;	:
655	660	early	early	RB
660	661	)	)	)
661	662	,	,	,
663	666	and	and	CC
667	671	both	both	DT
672	680	remained	remain	VBD
681	687	active	active	JJ
688	690	at	at	IN
691	696	later	late	JJR
697	701	time	time	NN
702	708	points	point	NNS
709	710	(	(	(
710	712	40	40	CD
713	714	h	h	NN
714	715	;	;	:
716	720	late	late	RB
720	721	)	)	)
722	727	after	after	IN
728	738	activation	activation	NN
738	739	.	.	.

740	744	This	this	DT
745	755	regulation	regulation	NN
756	761	takes	take	VBZ
762	767	place	place	NN
768	774	mainly	mainly	RB
775	777	at	at	IN
778	781	the	the	DT
782	787	level	level	NN
788	790	of	of	IN
791	798	nuclear	nuclear	JJ
799	812	translocation	translocation	NN
813	815	of	of	IN
816	819	p65	p65	NN
820	823	and	and	CC
824	829	c-rel	c-rel	NN
829	830	,	,	,
831	833	at	at	IN
834	843	immediate	immediate	JJ
844	847	and	and	CC
848	853	early	early	JJ
854	858	time	time	NN
859	865	points	point	NNS
865	866	.	.	.

867	877	Activation	Activation	NNP
878	882	also	also	RB
883	890	induced	induce	VBD
891	896	c-rel	c-rel	NN
897	900	and	and	CC
901	909	p105/p50	p105/p50	NN
910	914	mRNA	mrna	NN
915	924	synthesis	synthesis	NN
924	925	,	,	,
926	929	but	but	CC
930	933	not	not	RB
934	937	p65	p65	NN
938	942	mRNA	mrna	NN
943	948	whose	whose	WP$
949	959	expression	expression	NN
960	963	was	be	VBD
964	976	constitutive	constitutive	JJ
976	977	.	.	.

978	991	Interestingly	interestingly	RB
991	992	,	,	,
993	996	all	all	PDT
997	1002	those	those	DT
1003	1008	early	early	JJ
1009	1012	and	and	CC
1013	1017	late	late	JJ
1018	1024	events	event	NNS
1024	1025	,	,	,
1026	1029	but	but	CC
1030	1033	not	not	RB
1034	1037	the	the	DT
1038	1047	immediate	immediate	JJ
1048	1052	ones	one	NNS
1052	1053	,	,	,
1054	1058	were	be	VBD
1059	1068	inhibited	inhibit	VBN
1069	1071	by	by	IN
1072	1073	a	a	DT
1074	1086	neutralizing	neutralize	VBG
1087	1097	anti-tumor	anti-tumor	JJ
1098	1106	necrosis	necrosis	NN
1107	1113	factor	factor	NN
1114	1119	alpha	alpha	NN
1120	1121	(	(	(
1121	1130	TNF-alpha	TNF-alpha	NNP
1130	1131	)	)	)
1132	1142	monoclonal	monoclonal	JJ
1143	1151	antibody	antibody	NN
1151	1152	.	.	.

1153	1162	Similarly	similarly	RB
1162	1163	,	,	,
1164	1177	cycloheximide	cycloheximide	NN
1178	1187	prevented	prevent	VBD
1188	1191	the	the	DT
1192	1195	p65	p65	NN
1196	1199	and	and	CC
1200	1205	c-rel	c-rel	NN
1206	1219	translocation	translocation	NN
1220	1223	and	and	CC
1224	1234	consequent	consequent	JJ
1235	1244	formation	formation	NN
1245	1247	of	of	IN
1248	1254	active	active	JJ
1255	1262	binding	binding	NN
1263	1275	heterodimers	heterodimer	NNS
1275	1276	,	,	,
1277	1279	at	at	IN
1280	1285	early	early	JJ
1286	1289	and	and	CC
1290	1294	late	late	JJ
1295	1300	times	time	NNS
1300	1301	.	.	.

1302	1313	Cyclosporin	Cyclosporin	NNP
1314	1315	A	A	NNP
1316	1324	impaired	impair	VBD
1325	1328	not	not	RB
1329	1333	only	only	RB
1334	1339	early	early	JJ
1340	1343	and	and	CC
1344	1348	late	late	JJ
1348	1349	,	,	,
1350	1353	but	but	CC
1354	1358	also	also	RB
1359	1368	immediate	immediate	JJ
1369	1375	events	event	NNS
1375	1376	;	;	:
1377	1384	however	however	RB
1384	1385	,	,	,
1386	1394	addition	addition	NN
1395	1397	of	of	IN
1398	1407	TNF-alpha	TNF-alpha	NNP
1408	1417	prevented	prevent	VBD
1418	1421	all	all	DT
1422	1432	inhibition	inhibition	NN
1432	1433	.	.	.

1434	1439	These	these	DT
1440	1447	results	result	NNS
1448	1456	indicate	indicate	VBP
1457	1461	that	that	IN
1462	1465	the	the	DT
1466	1476	regulation	regulation	NN
1477	1479	of	of	IN
1480	1488	NF-kappa	NF-kappa	NNP
1489	1490	B	B	NNP
1491	1501	activation	activation	NN
1502	1508	during	during	IN
1509	1510	T	t	NN
1511	1515	cell	cell	NN
1516	1526	activation	activation	NN
1527	1529	by	by	IN
1530	1537	TcR/CD3	tcr/cd3	NN
1538	1545	signals	signal	NNS
1546	1548	is	be	VBZ
1549	1557	biphasic	biphasic	JJ
1557	1558	:	:	:
1559	1566	TcR/CD3	TcR/CD3	NNP
1567	1575	triggers	trigger	VBZ
1576	1579	its	its	PRP$
1580	1589	immediate	immediate	JJ
1590	1603	translocation	translocation	NN
1603	1604	,	,	,
1605	1610	which	which	WDT
1611	1613	is	be	VBZ
1614	1623	transient	transient	JJ
1624	1626	if	if	IN
1627	1629	no	no	DT
1630	1639	TNF-alpha	TNF-alpha	NNP
1640	1642	is	be	VBZ
1643	1650	present	present	JJ
1650	1651	.	.	.

1652	1661	TNF-alpha	TNF-alpha	NNP
1661	1662	,	,	,
1663	1672	therefore	therefore	RB
1672	1673	,	,	,
1674	1681	emerges	emerge	VBZ
1682	1684	as	as	IN
1685	1688	the	the	DT
1689	1693	main	main	JJ
1694	1700	factor	factor	NN
1701	1712	responsible	responsible	JJ
1713	1716	for	for	IN
1717	1718	a	a	DT
1719	1725	second	second	JJ
1726	1731	phase	phase	NN
1732	1734	of	of	IN
1735	1743	NF-kappa	NF-kappa	NNP
1744	1745	B	B	NNP
1746	1756	regulation	regulation	NN
1756	1757	,	,	,
1758	1769	controlling	control	VBG
1770	1774	both	both	CC
1775	1788	translocation	translocation	NN
1789	1791	of	of	IN
1792	1795	p65	p65	NN
1796	1799	and	and	CC
1800	1805	c-rel	c-rel	NN
1805	1806	,	,	,
1807	1810	and	and	CC
1811	1814	new	new	JJ
1815	1819	mRNA	mrna	NN
1820	1829	synthesis	synthesis	NN
1830	1833	for	for	IN
1834	1839	c-rel	c-rel	NN
1840	1843	and	and	CC
1844	1852	p105/p50	p105/p50	NN
1852	1853	.	.	.